URGN Stock: Price, Earnings History and SEC Filings
UroGen Pharma Ltd. (URGN) last traded at $32.72, down 2.27% on the latest session and down 19.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.28 against an analyst estimate of $-0.38, a beat of 26.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
URGN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.28 | $-0.38 | +26.32% |
| Mar 2026 | May 6, 2026 | $-0.47 | $-0.56 | +16.07% |
| Dec 2025 | Mar 2, 2026 | $-0.54 | $-0.66 | +18.18% |
| Sep 2025 | Nov 6, 2025 | $-0.69 | $-0.72 | +4.17% |
URGN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How URGN reacts to earnings
Across its last 8 earnings releases, URGN moved 9.6% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | +16.31% |
| 2026-05-06 | Before open | +10.16% |
| 2026-03-02 | Before open | -12.35% |
| 2025-11-06 | Before open | +21.91% |
| 2025-08-07 | Before open | -7.10% |
| 2025-05-12 | Before open | +7.32% |
| 2025-03-10 | Before open | +1.02% |
| 2024-11-06 | Before open | +0.25% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
URGN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $110M | -$153M | -$163M | -139.8% | – |
| 2024 | $90M | -$127M | -$97M | -140.4% | – |
| 2023 | $83M | -$102M | -$77M | -123.6% | – |
| 2022 | $64M | -$110M | -$88M | -170.6% | – |
| 2021 | $48M | -$111M | -$86M | -230.7% | – |
| 2020 | $12M | -$128M | -$107M | -1088.9% | – |
| 2019 | $18000 | -$105M | -$71M | -584144.4% | – |
| 2018 | $1M | -$76M | -$38M | -6707.2% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for URGN
- 8-K · Aug 20, 2026Other events
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 23, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · Jun 2, 2026Other events
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 30, 2026
- 10-K · Mar 2, 2026
- 8-K · Mar 2, 2026Results of operations, Financial statements and exhibits
Insider filing activity
URGN insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
URGN news
- Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial CancerOct 28, 2026 · finance.yahoo.com
- UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026Oct 27, 2026 · finance.yahoo.com
- Why UroGen Pharma (URGN) Is Getting Fresh Attention NowOct 20, 2026 · finance.yahoo.com
- UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBCOct 19, 2026 · finance.yahoo.com
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Israel. Its fiscal year ends in December.